You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Untreated Advanced Melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Melanoma, Unresectable Melanoma, Melanoma Trial (Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover

Not yet recruiting
  • Metastatic Melanoma
  • +2 more
  • Lifileucel plus Pembrolizumab
  • Pembrolizumab with Optional Crossover Period
  • (no location specified)
Feb 13, 2023

Melanoma Trial in Orlando, Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

Recruiting
  • Melanoma
  • Orlando, Florida
  • +1 more
Jul 5, 2022

Advanced Melanoma Trial in Worldwide (IMC-F106C, Nivolumab, Nivolumab + Relatlimab)

Not yet recruiting
  • Advanced Melanoma
  • IMC-F106C
  • +2 more
  • La Jolla, California
  • +61 more
Oct 31, 2023

Uveal Melanoma Trial in Pittsburgh (Tebentafusp)

Not yet recruiting
  • Uveal Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Oct 5, 2023

Melanoma Trial in Changchun (Camrelizumab, Anlotinib, nab-Paclitaxel)

Recruiting
  • Melanoma
  • Changchun, Jilin, China
    The first hospital of Jilin University
Jul 27, 2021

Malignant Melanoma Trial in Worldwide (Atezolizumab, Cobimetinib)

Completed
Has Results
  • Malignant Melanoma
  • Scottsdale, Arizona
  • +42 more
Nov 17, 2021

Melanoma Trial in Beijing (IBI363)

Not yet recruiting
  • Melanoma
  • IBI363
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 7, 2023

Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

Not yet recruiting
  • Melanoma
  • Fluzoparib Camrelizumab Temozolomide
  • (no location specified)
Aug 9, 2023

Gut and Tumor Microbiome in Advanced ER-positive and

Not yet recruiting
  • Breast Cancer
  • Melanoma
  • Observation
  • (no location specified)
Nov 6, 2023

Melanoma, Malignant Melanoma Trial (T3011 + Cobimetinib)

Not yet recruiting
  • Melanoma
  • Malignant Melanoma
  • T3011 + Cobimetinib
  • (no location specified)
Mar 3, 2023

Advanced Melanoma Trial in Basel (Combination of Tumor-infiltrating lymphocyte transfer with ANV419)

Not yet recruiting
  • Advanced Melanoma
  • Combination of Tumor-infiltrating lymphocyte transfer with ANV419
  • Basel, Switzerland
    University Hospital Basel
May 19, 2023

Untreated Advanced NSCLC Trial in Fuzhou (Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and

Recruiting
  • Untreated Advanced Non-small Cell Lung Cancer
  • Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Nov 13, 2023

Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)

Not yet recruiting
  • Acral Melanoma
  • (no location specified)
Mar 16, 2023

Melanoma Trial in Beijing (tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin)

Not yet recruiting
  • Melanoma
  • tunlametinib
  • paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 15, 2023

Uveal Melanoma Trial in Worldwide (IMCgp100, Dacarbazine, Ipilimumab)

Active, not recruiting
Has Results
  • Uveal Melanoma
  • IMCgp100
  • +3 more
  • Los Angeles, California
  • +55 more
Mar 10, 2022

Melanoma Trial in United States (IO102/IO103, Nivolumab-Relatlimab)

Recruiting
  • Melanoma
  • Basking Ridge, New Jersey
  • +6 more
Jun 23, 2023

Melanoma Trial in North Sydney, Woolloongabba, Wellington (RO7247669)

Recruiting
  • Melanoma
  • North Sydney, New South Wales, Australia
  • +12 more
Jan 30, 2023

Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)

Active, not recruiting
  • Tumor Skin
  • +2 more
  • OBX-115
  • Orlando, Florida
  • +1 more
Sep 28, 2023

Untreated Advanced or Recurrent Thymic Carcinomas Trial in Chuo (MK-3475, Lenvatinib, Carboplatin)

Not yet recruiting
  • Untreated Advanced or Recurrent Thymic Carcinomas
  • Chuo, Tokyo, Japan
    National Cancer Center Hospital
Apr 16, 2023

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

Not yet recruiting
  • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
  • Ivosidenib 500mg
  • Placebo
  • (no location specified)
Nov 7, 2023

Melanoma Trial in Beijing (KD6001, Toripalimab)

Not yet recruiting
  • Melanoma
  • Beijing, China
    Beijing Cancer Hospital
Feb 3, 2023

Melanoma Trial in Philadelphia (Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Mature dendritic cell (DC) vaccine
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 2, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects Trial in Shanghai (Tumor Infiltrating Lymphocyte)

Recruiting
  • Advanced Melanoma
  • +3 more
  • Tumor Infiltrating Lymphocyte
  • Shanghai, China
    Shanghai Tenth People's Hospital
Dec 19, 2022

Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)

Not yet recruiting
  • Advanced Mucosal Melanoma
  • Envafolimab combined with recombinant human endostatin and first-line chemotherapy
  • (no location specified)
Sep 15, 2023